Tacrolimus targeted half-dose + Tacrolimus targeted plain dose
ApprovedUNKNOWN 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
De Novo Transplant Disease
Conditions
De Novo Transplant Disease
Trial Timeline
May 1, 2012 → Mar 1, 2015
NCT ID
NCT01744470About Tacrolimus targeted half-dose + Tacrolimus targeted plain dose
Tacrolimus targeted half-dose + Tacrolimus targeted plain dose is a approved stage product being developed by Astellas Pharma for De Novo Transplant Disease. The current trial status is unknown. This product is registered under clinical trial identifier NCT01744470. Target conditions include De Novo Transplant Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02154854 | Approved | UNKNOWN |
| NCT01744470 | Approved | UNKNOWN |
Competing Products
19 competing products in De Novo Transplant Disease